ATE206932T1 - Formulierung von stabilisierter kationischen transfektionsmittel/nukleinsäuren partikeln - Google Patents

Formulierung von stabilisierter kationischen transfektionsmittel/nukleinsäuren partikeln

Info

Publication number
ATE206932T1
ATE206932T1 AT98906986T AT98906986T ATE206932T1 AT E206932 T1 ATE206932 T1 AT E206932T1 AT 98906986 T AT98906986 T AT 98906986T AT 98906986 T AT98906986 T AT 98906986T AT E206932 T1 ATE206932 T1 AT E206932T1
Authority
AT
Austria
Prior art keywords
transfection agent
formulation
acid particles
cationic transfection
nuclic acid
Prior art date
Application number
AT98906986T
Other languages
English (en)
Inventor
Joel Crouzet
Bruno Pitard
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9503492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE206932(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE206932T1 publication Critical patent/ATE206932T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT98906986T 1997-02-10 1998-02-06 Formulierung von stabilisierter kationischen transfektionsmittel/nukleinsäuren partikeln ATE206932T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9701467A FR2759298B1 (fr) 1997-02-10 1997-02-10 Formulation de particules agent(s) de transfection cationique(s)/acides nucleiques stabilisees
PCT/FR1998/000222 WO1998034648A1 (fr) 1997-02-10 1998-02-06 Formulation de particules agent(s) de transfection cationique(s)/acides nucleiques stabilisees

Publications (1)

Publication Number Publication Date
ATE206932T1 true ATE206932T1 (de) 2001-11-15

Family

ID=9503492

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98906986T ATE206932T1 (de) 1997-02-10 1998-02-06 Formulierung von stabilisierter kationischen transfektionsmittel/nukleinsäuren partikeln

Country Status (20)

Country Link
EP (1) EP1007097B1 (de)
JP (1) JP2001511171A (de)
KR (1) KR20000070914A (de)
AT (1) ATE206932T1 (de)
AU (1) AU737720B2 (de)
BR (1) BR9807563A (de)
CA (1) CA2278665A1 (de)
CZ (1) CZ282199A3 (de)
DE (1) DE69802102T2 (de)
DK (1) DK1007097T3 (de)
ES (1) ES2166146T3 (de)
FR (1) FR2759298B1 (de)
GR (1) GR3036919T3 (de)
HU (1) HUP0001720A3 (de)
IL (1) IL130765A0 (de)
NO (1) NO993825D0 (de)
PT (1) PT1007097E (de)
SK (1) SK282685B6 (de)
WO (1) WO1998034648A1 (de)
ZA (1) ZA981034B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
WO1999052858A2 (en) * 1998-04-08 1999-10-21 Celltech Therapeutics Limited Lipids
AU747597B2 (en) * 1998-07-20 2002-05-16 Inex Pharmaceuticals Corporation Liposomal encapsulated nucleic acid-complexes
AU2001241958A1 (en) * 2000-03-03 2001-09-17 Valentis, Inc. Improved poloxamer and poloxamine compositions for nucleic acid delivery
GB0009201D0 (en) * 2000-04-14 2000-05-31 Univ Nottingham Cationic polymer - Nucleic acid complexes and methods of making them
US20020091242A1 (en) 2000-10-11 2002-07-11 Michel Bessodes Acid-sensitive compounds, their preparation and uses
CA2426582A1 (en) * 2000-10-20 2002-08-08 Valentis, Inc. Gene delivery formulations and methods for treatment of ischemic conditions
EP1232758A1 (de) * 2001-02-19 2002-08-21 Aventis Pasteur Polynukleotid-Formulierung für verbesserte intrazellulare Übertragung
JP2007527431A (ja) 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP4653242B1 (ja) 2010-02-12 2011-03-16 ナノキャリア株式会社 粒子状医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181937A3 (de) * 1994-08-09 2004-02-04 Cytrx Corporation Nukleinsäure enthaltender Impfstoff, Impfstoff-adjuvans
AU5527696A (en) * 1995-03-31 1996-10-16 Children's Hospital Medical Center Use of surfactants for introducing genetic material into lun g cells
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells

Also Published As

Publication number Publication date
ES2166146T3 (es) 2002-04-01
SK282685B6 (sk) 2002-11-06
HUP0001720A3 (en) 2001-10-29
AU737720B2 (en) 2001-08-30
NO993825L (no) 1999-08-09
BR9807563A (pt) 2000-02-01
EP1007097B1 (de) 2001-10-17
PT1007097E (pt) 2002-04-29
DE69802102D1 (de) 2001-11-22
DE69802102T2 (de) 2002-03-14
WO1998034648A1 (fr) 1998-08-13
AU6298798A (en) 1998-08-26
EP1007097A1 (de) 2000-06-14
CZ282199A3 (cs) 1999-10-13
JP2001511171A (ja) 2001-08-07
IL130765A0 (en) 2001-01-28
FR2759298B1 (fr) 1999-04-09
HUP0001720A1 (hu) 2000-09-28
NO993825D0 (no) 1999-08-09
ZA981034B (en) 1998-08-11
CA2278665A1 (fr) 1998-08-13
GR3036919T3 (en) 2002-01-31
FR2759298A1 (fr) 1998-08-14
KR20000070914A (ko) 2000-11-25
DK1007097T3 (da) 2002-02-11
SK108299A3 (en) 2000-05-16

Similar Documents

Publication Publication Date Title
ATE206932T1 (de) Formulierung von stabilisierter kationischen transfektionsmittel/nukleinsäuren partikeln
IL172835A0 (en) A composition for stabilizing active protein ingredients in pharmaceutical composition containing at least 2 amino acids
PT1123120E (pt) Formulacao medicinal em aerossol
MX9804848A (es) Emulsiones estables que comprenden un ingrediente liquido hidrofobico.
EP0911039A3 (de) Wirkstoff-Harzkomplexe stabilisiert mit Chelatbildner
ZA979550B (en) Method for the preparation of methylidene malonate nanoparticles, nanoparticles which optionally contain one or more biologically active molecules, and pharmaceutical compositions containing them.
WO1998038984A3 (en) Formulations for hydrophobic pharmaceutical agents
TR199501321A2 (tr) Farmasötik bilesimler.
GR3007107T3 (de)
WO2000032186A3 (en) Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
BR0207699A (pt) Produto para aplicação axilar
BR0015538A (pt) Emprego de polissiloxanos com grupos amino quaternários como coadjuvantes de formulação, e agentes contendo-os
DK0799035T3 (da) Emulsion egnet til indgivelse af et sphingolipid og anvendelse deraf
ATE245028T1 (de) Trimegestone enthaltende pharmazeutische zusammensetzungen
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
KR960013376A (ko) 철과 디프룩토오스를 함유하는 빈혈치료제
ZA903334B (en) Cleansing composition
BR9811985A (pt) Dispositivo de dosagem
TR199801460T2 (xx) Renk stabilize edici(ler) ve s�rfaktan(lar)� i�eren temizleyici bile�im.
DK0575481T3 (da) Flydende præparater baseret på derivater af 1,4-substitueret piperidin
DK0457127T3 (da) Spermicidt belægningsmiddel
WO1998023260A3 (en) Non-ionic surfactant vesicles as a delivery agent for nucleic acid
ATE310075T1 (de) Reinigungsmittelkomponente mit feinteiligen feststoffen
Gorshkov et al. Effects of Nitrogen-Containing Compounds on H sub 2 PtCl sub 6 Activity in Hydrosilication of Unsaturated Siloxane Rubbers
ATE96722T1 (de) Mischung fuer den holzschutz.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee